FDA Rejects Galderma's Botox Rival Relfydess Again, Citing Manufacturing Inspection Issues

Second Rejection in Three Years

Galderma's bid to bring Relfydess to the U.S. market hit another wall on July 1, 2026. The FDA issued a Complete Response Letter declining the company's Biologics License Application for RelabotulinumtoxinA, the product marketed internationally as Relfydess.

In 2023, the FDA turned down a prior submission over deficiencies in chemistry, manufacturing, and controls processes, according to Dow Jones Newswires via Morningstar. This latest rejection stems from observations made during a Pre-License Inspection of Galderma's manufacturing site, plus concerns about analytical method optimization.

What the FDA Actually Found

Galderma's own announcement, filed as an ad hoc disclosure with the Swiss Exchange, is specific about what the FDA flagged: manufacturing site inspection observations and analytical method optimization. The company states that all other parts of the BLA, including safety and efficacy data, "did not solicit deficiencies to be addressed."

The rejection is not on medical grounds. The underlying science passed. The obstacle is on the manufacturing compliance side, which is a different category of problem.

Galderma says it is putting corrective and preventive actions in place and will seek continued dialogue with the FDA toward resolution.

Where Relfydess Already Stands

Outside the U.S., this product has been moving. As of July 1, 2026, Relfydess is approved in 33 markets and launched in more than 20, including Europe, the United Kingdom, the Middle East, Asia, and Australia, according to Galderma's disclosure. The company notes that since 2022, the same manufacturing site has completed 10 inspections from regulatory authorities worldwide, all of which served as the basis for those international launches.

The FDA's observations do not affect any of those existing international approvals or ongoing regulatory reviews in other territories, Galderma states.

The Competitive Stakes

Relfydess is designed to rival AbbVie's Botox, which dominates the U.S. injectable aesthetics market. Galderma describes Relfydess as the first ready-to-use liquid neuromodulator, built on what it calls PEARL Technology, which it says is designed to preserve molecule integrity. Getting this product into the U.S. would give Galderma a meaningful competitive weapon against the entrenched market leader.

The U.S. injectable aesthetics market is large and growing. Every quarter Galderma spends in FDA limbo is a quarter AbbVie retains pricing power and market share without a direct challenge from this specific product.

The Fair Case for Galderma

Skeptics watching this company's second rejection in three years could reasonably wonder whether this is a systemic manufacturing competence problem rather than a fixable procedural issue. Two CRLs from the same regulatory body on the same product, even for different stated reasons, raises a legitimate question about execution.

Galderma's counter is concrete: the same manufacturing facility passed 10 international regulatory inspections since 2022, including inspections by agencies that approved the product for launch in major markets across Europe and Asia. If those agencies found the site acceptable, the gap with the FDA appears to be specific observations rather than a broader facility failure. Galderma's position deserves to be taken at face value until a resubmission reveals otherwise.

No Timeline Given

Galderma says it plans to "rapidly respond" to the CRL, but no specific resubmission date has been announced. FDA response timelines after a Complete Response Letter typically run months, not weeks, and a new inspection would likely be required before approval could proceed.

Galderma's shares fell on the news, according to SWI swissinfo.ch, though the company's press materials emphasize that its broader pipeline and international business remain unaffected.

The unresolved question is whether Galderma's corrective actions satisfy the FDA's specific inspection findings, or whether the agency's next review surfaces additional manufacturing concerns. That answer will determine whether Relfydess competes in the world's largest aesthetics market before 2027.